Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Construction in Progress (2018 - 2023)

China SXT Pharmaceuticals (SXTC) has 6 years of Construction in Progress data on record, last reported at $349390.0 in Q1 2023.

  • For Q1 2023, Construction in Progress fell 3.77% year-over-year to $349390.0; the TTM value through Mar 2023 reached $349390.0, down 3.77%, while the annual FY2023 figure was $349390.0, 3.77% down from the prior year.
  • Construction in Progress reached $349390.0 in Q1 2023 per SXTC's latest filing, down from $363078.0 in the prior quarter.
  • Across five years, Construction in Progress topped out at $649235.0 in Q1 2019 and bottomed at $328372.0 in Q1 2020.
  • Average Construction in Progress over 5 years is $409137.8, with a median of $355614.0 recorded in 2021.
  • Peak YoY movement for Construction in Progress: crashed 49.42% in 2020, then grew 8.3% in 2021.
  • A 5-year view of Construction in Progress shows it stood at $649235.0 in 2019, then plummeted by 49.42% to $328372.0 in 2020, then rose by 8.3% to $355614.0 in 2021, then grew by 2.1% to $363078.0 in 2022, then fell by 3.77% to $349390.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Construction in Progress were $349390.0 in Q1 2023, $363078.0 in Q1 2022, and $355614.0 in Q1 2021.